EWTX NASDAQ
Edgewise Therapeutics, Inc.
1W: -0.6%
1M: -0.7%
3M: -0.6%
YTD: +66.4%
1Y: +160.4%
3Y: +478.8%
5Y: +143.3%
$39.53
+0.36 (+0.92%)
After Hours: $38.52 (-1.01, -2.54%)
Weekly Expected Move ±5.6%
$35
$37
$39
$41
$44
Credit Risk of going bust: lower than 83% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Edgewise Therapeutics, Inc. would be worth roughly what it owes.
Total debt $3.6M against a stock market value of $4.21B.
Distance to default 10.49 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 72.0%; Altman Z'' 13.74. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Edgewise Therapeutics, Inc. would be worth roughly what it owes.
Total debt $3.6M against a stock market value of $4.21B.
Distance to default 10.49 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 72.0%; Altman Z'' 13.74. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.3B
52W Range15.66-48.51
Volume691,740
Avg Volume1,363,437
Beta0.28
Dividend—
Analyst Ratings
Company Info
CEOKevin Koch
Employees127
SectorHealthcare
IndustryBiotechnology
IPO Date2021-03-26
Websiteedgewisetx.com
1715 38th Street
Boulder, CO 80301
US
Boulder, CO 80301
US
303 735 8373
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Latest News
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Bank of America Corp DE Takes Position in Edgewise Therapeutics, Inc. $EWTX
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC
12,365 Shares in Edgewise Therapeutics, Inc. $EWTX Purchased by Corient Private Wealth LP
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fox Jonathan C | A-Award | 308 | — | 2026-10-01 |
| Donovan Joanne M. | S-Sale | 2,919 | $43.41 | 2026-08-13 |
| Nofi Michael | A-Award | 48,750 | $43.56 | 2026-08-12 |
| Donovan Joanne M. | A-Award | 65,000 | $43.56 | 2026-08-12 |
| Russell Alan J | A-Award | 65,000 | $43.56 | 2026-08-12 |